India Pharma Outlook Team | Friday, 01 August 2025
Iberia Pharmaceuticals is establishing a modern skincare manufacturing and research plant in Jhajjar Haryana to enhance its presence in India in the skincare sector.
The modern unit will include 60,000 sq. ft. and be established with an investment of 70 crore rupees and is planned to be launched in the middle of 2026.
This growth is in line with the government construct of make-in-India and it reflects the decision of Iberia in the direction of local manufacturing quality.
Also Read: Pharmaceutical Procurement Strategies: How to Optimize Costs
“This new plant marks a major milestone in our growth journey,” said Nitin Jain, Founder of Iberia Pharmaceuticals.
Designed to be scalable and accurate, with world-class control systems and state-of-the-art machinery, the new plant will have the capacity to produce many units of above 12 million per year with all international standards maintained. Iberia pharmaceuticals will specialize in dermatology, chronic care, and wellness formulations to be available in both the domestic and international markets.
Co-founder Saurav Ojha said, “At Iberia Pharmaceuticals, our purpose is clear—we want to deliver healthcare solutions that are precise, safe, and responsible. Our new advanced manufacturing and research facility stands as a symbol of that commitment.”
The facility will consist of R&D laboratories at the core, which will be next-generation laboratories based on innovation, trend tracking, and incessant product enhancement. With a leading edge in nanotechnology skincare, Iberia offers vegan products, pharmaceutical-grade ingredients, and clinically tested products to meet the changing demands of consumers.
The increased Indian portfolio of Iberia involves trusted worldwide brands such as Sesderma, Mediderma, Dermpix, Noreva, and Metacare—complying with dermatologists, wellness clinics, and skincare experts.
